Among low-risk patients with aortic stenosis, TAVR was superior to SAVR in preventing death, stroke, or rehospitalization at 1 year and was sustained to 2 years
TAVR was also associated with a lower incidence of stroke and atrial fibrillation, and a shorter hospital length of stay compared with SAVR
TAVR was associated with a larger improvement in quality of life compared with SAVR
There was a numerical increase in the need for new permanent pacemaker within 30 days in the TAVR group (6.5% with TAVR vs. 4.0% with SAVR); however, this difference was not statistically significant
Mild paravalvular aortic regurgitation occurred at a higher incidence in the TAVR group. The incidence of moderate to severe aortic regurgitation was rare (<1%) and similar between treatment groups
As compared to TAVR, SAVR was associated with an increased incidence of valve thrombosis (VARC-2 definition) and increased mean transvalvular gradient at 2 years
Placement of Aortic Transcatheter Valves 3. American College of Cardiology. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2fclinical-trials%2f2019%2f03%2f15%2f18%2f29%2fpartner-3. Accessed May 4, 2020.
ACC.20/WCC Presentation Slides | PARTNER 3. American College of Cardiology. http%3a%2f%2fwww.acc.org%2feducation-and-meetings%2fimage-and-slide-gallery%2fmedia-detail%3fid%3d8a466af94dc2424bb8957265b09122d9. Accessed May 4, 2020.